Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OptiNose Inc OPTN

Healthcare
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and... see more

Recent & Breaking News (NDAQ:OPTN)

Optinose to Report Second Quarter 2018 Financial Results and Corporate Updates on August 14, 2018

GlobeNewswire August 7, 2018

Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal

GlobeNewswire July 2, 2018

Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals

GlobeNewswire June 21, 2018

Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The Year 2018 in Greater

GlobeNewswire June 15, 2018

Optinose Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares

GlobeNewswire June 11, 2018

Optinose Announces Pricing of Public Offering of Common Stock

GlobeNewswire June 6, 2018

Optinose Announces Launch of Public Offering of Common Stock

GlobeNewswire June 4, 2018

Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights

GlobeNewswire May 14, 2018

OptiNose, Inc. to Host Earnings Call

Accesswire May 14, 2018

Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018

GlobeNewswire May 7, 2018

Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania

GlobeNewswire March 15, 2018

Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights

GlobeNewswire March 13, 2018

Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018

GlobeNewswire March 6, 2018

Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress

GlobeNewswire February 27, 2018

Optinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit Committee

GlobeNewswire February 22, 2018

Peter Miller Named Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania

GlobeNewswire February 20, 2018

Optinose to Present at the 2018 RBC Capital Markets Healthcare Conference

GlobeNewswire February 15, 2018

Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference

GlobeNewswire February 9, 2018

Optinose Announces $100 Million Debt Financing from Athyrium Capital Management

GlobeNewswire January 2, 2018

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors

GlobeNewswire December 11, 2017